Survival Advantage With Decitabine Versus Intensive Chemotherapy in Patients With Higher Risk Myelodysplastic Syndrome
Cancer- United States
doi 10.1002/cncr.22508
Full Text
Abstract
Available in
Date
March 15, 2007
Authors
Publisher
Wiley
doi 10.1002/cncr.22508
Available in
March 15, 2007
Wiley